Prolonging ticagrelor beyond a year of acute coronary syndrome: Worth or harmful?

Dániel Aradi, Döme Dézsi, Gábor Veress, B. Merkely

Research output: Contribution to journalReview article

Abstract

Platelet activation plays a central role in triggering and complicating acute coronary syndromes, especially in case of stent thrombosis and myocardial infarction. On top of aspirin, P2Y12-inhibitors are successfully used to treat and prevent these events for a duration of one year after an acute coronary episode or 6 months after drug-eluting stent implantation. However, patients with acute coronary syndromes remain at heightened risk for recurrent ischemic events after the recommended durations of P2Y12-inhibitors and therefore, prolonging treatment is often considered in clinical practice. However, the higher risk for bleeding limits the utility of such approach to a restricted group who is still poorly defined by available measures. This review aims to discuss potential benefits and highlight important pitfalls of prolonged treatment with P2Y12-inhibitors, with a focus on ticagrelor, an attractive reversible P2Y12-inhibitor in patients after myocardial infarction.

Original languageEnglish
Pages (from-to)446-450
Number of pages5
JournalCurrent Vascular Pharmacology
Volume16
Issue number5
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Acute Coronary Syndrome
Myocardial Infarction
Drug-Eluting Stents
Platelet Activation
Aspirin
Stents
Thrombosis
Hemorrhage
Therapeutics
Ticagrelor

Keywords

  • Bleeding
  • Clopidogrel
  • Late outcomes
  • PCI
  • Prasugrel
  • Thrombosis
  • Ticagrelor

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Prolonging ticagrelor beyond a year of acute coronary syndrome : Worth or harmful? / Aradi, Dániel; Dézsi, Döme; Veress, Gábor; Merkely, B.

In: Current Vascular Pharmacology, Vol. 16, No. 5, 01.01.2018, p. 446-450.

Research output: Contribution to journalReview article

Aradi, Dániel ; Dézsi, Döme ; Veress, Gábor ; Merkely, B. / Prolonging ticagrelor beyond a year of acute coronary syndrome : Worth or harmful?. In: Current Vascular Pharmacology. 2018 ; Vol. 16, No. 5. pp. 446-450.
@article{424449c1ce3143538792418b6b70a699,
title = "Prolonging ticagrelor beyond a year of acute coronary syndrome: Worth or harmful?",
abstract = "Platelet activation plays a central role in triggering and complicating acute coronary syndromes, especially in case of stent thrombosis and myocardial infarction. On top of aspirin, P2Y12-inhibitors are successfully used to treat and prevent these events for a duration of one year after an acute coronary episode or 6 months after drug-eluting stent implantation. However, patients with acute coronary syndromes remain at heightened risk for recurrent ischemic events after the recommended durations of P2Y12-inhibitors and therefore, prolonging treatment is often considered in clinical practice. However, the higher risk for bleeding limits the utility of such approach to a restricted group who is still poorly defined by available measures. This review aims to discuss potential benefits and highlight important pitfalls of prolonged treatment with P2Y12-inhibitors, with a focus on ticagrelor, an attractive reversible P2Y12-inhibitor in patients after myocardial infarction.",
keywords = "Bleeding, Clopidogrel, Late outcomes, PCI, Prasugrel, Thrombosis, Ticagrelor",
author = "D{\'a}niel Aradi and D{\"o}me D{\'e}zsi and G{\'a}bor Veress and B. Merkely",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1570161116666180117104613",
language = "English",
volume = "16",
pages = "446--450",
journal = "Current Vascular Pharmacology",
issn = "1570-1611",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Prolonging ticagrelor beyond a year of acute coronary syndrome

T2 - Worth or harmful?

AU - Aradi, Dániel

AU - Dézsi, Döme

AU - Veress, Gábor

AU - Merkely, B.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Platelet activation plays a central role in triggering and complicating acute coronary syndromes, especially in case of stent thrombosis and myocardial infarction. On top of aspirin, P2Y12-inhibitors are successfully used to treat and prevent these events for a duration of one year after an acute coronary episode or 6 months after drug-eluting stent implantation. However, patients with acute coronary syndromes remain at heightened risk for recurrent ischemic events after the recommended durations of P2Y12-inhibitors and therefore, prolonging treatment is often considered in clinical practice. However, the higher risk for bleeding limits the utility of such approach to a restricted group who is still poorly defined by available measures. This review aims to discuss potential benefits and highlight important pitfalls of prolonged treatment with P2Y12-inhibitors, with a focus on ticagrelor, an attractive reversible P2Y12-inhibitor in patients after myocardial infarction.

AB - Platelet activation plays a central role in triggering and complicating acute coronary syndromes, especially in case of stent thrombosis and myocardial infarction. On top of aspirin, P2Y12-inhibitors are successfully used to treat and prevent these events for a duration of one year after an acute coronary episode or 6 months after drug-eluting stent implantation. However, patients with acute coronary syndromes remain at heightened risk for recurrent ischemic events after the recommended durations of P2Y12-inhibitors and therefore, prolonging treatment is often considered in clinical practice. However, the higher risk for bleeding limits the utility of such approach to a restricted group who is still poorly defined by available measures. This review aims to discuss potential benefits and highlight important pitfalls of prolonged treatment with P2Y12-inhibitors, with a focus on ticagrelor, an attractive reversible P2Y12-inhibitor in patients after myocardial infarction.

KW - Bleeding

KW - Clopidogrel

KW - Late outcomes

KW - PCI

KW - Prasugrel

KW - Thrombosis

KW - Ticagrelor

UR - http://www.scopus.com/inward/record.url?scp=85049978620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049978620&partnerID=8YFLogxK

U2 - 10.2174/1570161116666180117104613

DO - 10.2174/1570161116666180117104613

M3 - Review article

C2 - 29345592

AN - SCOPUS:85049978620

VL - 16

SP - 446

EP - 450

JO - Current Vascular Pharmacology

JF - Current Vascular Pharmacology

SN - 1570-1611

IS - 5

ER -